Select Your Region
Global
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
- Cancer
- Lung Cancer
- Non-Small Cell Lung Cancer (NSCLC)
Please note that the recruitment status of the trial at your site may differ.
Trial Status:
Active, not recruiting
This trial runs in
Cities
- Abu Dhabi
- Adana
- Alba Iulia
- Ankara
- Antalya
- Auderghem
- Barnaul
- Bedford Park
- Beograd
- Bogotá
- Brno
- București
- Buenos Aires
- Burgas
- Cagliari
- Cali
- Camperdown
- casalmaggiore
- chang-sha-shi
- Chelyabinsk
- Chieti
- Cluj-Napoca
- Cremona
- Denizli
- Edirne
- Genova
- Gent
- guang-zhou-shi
- Haifa
- hang-zhou-shi
- Hanoi
- Hasselt
- Havana
- he-fei-shi
- Hlavní město Praha
- Iași
- İstanbul
- İzmir
- Jinan
- Kaunas
- Klagenfurt am Wörthersee
- Konya
- Kortrijk
- Krasnoyarsk
- La Habana
- Lima
- Liverpool
- Lombardy
- Lucca
- luik
- Malatya
- Medellín
- Meldola
- Montevideo
- Moscow Oblast
- nan-jing-shi
- nan-ning-shi
- Niš
- north-melbourne
- Novara
- Olomouc
- olomouc-9
- Osijek
- Padova
- Padua
- Palermo
- Panagyurishte
- Panamá
- Perugia
- Petah Tikva
- Ploiești
- Plovdiv
- Porto
- Providencia
- Ramat Gan
- Reggio Calabria
- Roma
- Rome
- Ronse
- Saint Petersburg
- San Borja
- Santiago
- Sint-Niklaas
- Sofia
- Sremska Kamenica
- St Leonards
- Surquillo
- tai-zhou-shi
- Taiyuan
- Tampere
- Taranto
- Tel Aviv-Yafo
- Thành phố Hồ Chí Minh
- tian-jin-shi
- Timișoara
- Torrette
- Turku
- Tuscany
- Ufa
- Vila Nova de Gaia
- Vilnius
- Wien
- wu-han-shi
- Wuhan
- xu-zhou-shi
- Xuzhou
- Zagreb
- Zhejiang
- zheng-zhou-shi
- دبي
Trial Identifier:
NCT04764188 MO42122
Trial Summary
This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.
Hoffmann-La Roche
Sponsor
NCT04764188,MO42122
Trial Identifier
Alectinib
Treatments
NSCLC
Condition
Official Title
A Multicenter Non-Interventional Cohort Study to Evaluate the Real-World Clinical Management and Outcomes of Patients Diagnosed With ALK-Positive Advanced NSCLC Treated With Alectinib (ReAlec)
Eligibility Criteria
All
Gender
≥18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Confirmed diagnosis of advanced NSCLC (stage IIIB, IIIC, IVA, or IVB) on or after the date of local approval for alectinib as first-line treatment and/or second-line treatment for ALK-positive advanced NSCLC and planned to receive treatment as per routine for at least one cycle (28 days) while on study
- ALK-positive as confirmed by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), next generation sequencing (NGS), or other non-specified sequencing methods, documented prior to receiving treatment with an ALK inhibitor
- Cohort 1: Currently receiving, or planned to receive, treatment for ALK-positive advanced NSCLC with alectinib as first-line treatment
- Cohort 2: Planned to receive treatment for ALK-positive advanced NSCLC with alectinib as second-line treatment
- Able to be followed-up by participating site
- Participants with advanced NSCLC who have CNS metastases are eligible for inclusion
Exclusion Criteria
- Participants not receiving alectinib for the treatment of ALK-positive advanced NSCLC according to standard of care and in line with local product information
- Participants not receiving the Roche studied medicinal product
- Participants who have received or are currently receiving alectinib as an investigational study drug in a clinical trial for the treatment of advanced NSCLC
For the latest version of this information please go to www.forpatients.roche.com